在上衣细胞淋巴瘤患者的前线治疗后,易布鲁替尼布的维护
Reem Karmali1,2, Jeremy S Abramson3,4, Deborah M Stephens5
1Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Blood advances
|September 27, 2023
概括
易布鲁替尼维护疗法在上衣细胞淋巴瘤 (MCL) 患者中显示出高疗效,在初始治疗后实现缓解. 这种方法提供了优异的长期存活率与可管理的副作用,支持其在MCL管理中的使用.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 维护式利图西马布改善了上衣细胞淋巴瘤 (MCL) 的治疗结果.
- 正在探索新的维持剂,以进一步提高MCL的存活率.
- 易布鲁替尼维护 (I-M) 是未经治疗的MCL患者的潜在策略.
研究的目的:
- 评估在未接受治疗的地幔细胞淋巴瘤 (MCL) 患者中,布鲁丁尼布维护 (I-M) 的安全性和有效性.
- 评估IM启动后的3年无进展生存率 (PFS).
- 在IM期间监测最小残留疾病 (MRD) 动态.
主要方法:
- 在完全或部分响应的36名未经治疗的MCL患者接受了ibrutinib的维持治疗 (每天560毫克),长达4年.
- 无进展生存率 (PFS) 和总生存率 (OS) 是主要终点.
- 下一代测序 (NGS) 用于在I-M前和期间进行最小残留疾病 (MRD) 评估.
主要成果:
- 三年PFS和OS率分别为94%和97%.
- 在I-M之前接受了自身干细胞移植 (ASCT) 的患者有100%的3年PFS和OS.
- 感染是最常见的不良事件 (86%),血液毒性是最常见的3/4级事件.
结论:
- 易布鲁替尼维护是MCL患者前线治疗后可行的选择,证明了显著的疗效.
- 虽然毒性是可以管理的,但感染和血液问题需要注意.
- 最小残留疾病 (MRD) 监测显示了动态变化,大多数患者保持完全缓解.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


